Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-2 of 2
Keywords: Fludarabine
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
M. Rummel, M. Schenk, Ch. Renner, A. Knuth, K. Josten, U. Reinhardt, B. Rendenbach, H.-J. Pielken, C. Wojatschek, E. Lengfelder, P.S. Mitrou, D. Hoelzer, L. Bergmann
Journal:
Onkologie
Onkologie (1997) 20 (4): 328–331.
Published Online: 13 May 2009
...M. Rummel; M. Schenk; Ch. Renner; A. Knuth; K. Josten; U. Reinhardt; B. Rendenbach; H.-J. Pielken; C. Wojatschek; E. Lengfelder; P.S. Mitrou; D. Hoelzer; L. Bergmann Background: Fludarabine has been reported to be the most effective single agent in previously treated chronic lymphocytic leukemia...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1994) 17 (5): 508–513.
Published Online: 11 May 2009
...K. Fenchel; P. Wijermans; P.S. Mitrou; D. Hoelzer; L. Bergmann Background : Fludarabine monophosphate is a new adenine nucleoside analogue with promising efficacy in Waldenström’s macroglobulinemia with response rates of 31-45% in previously treated and up to 100% in previously untreated patients...